Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03818776 | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | terminated | Early Phase 1 | 7 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03564782 | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | completed | Early Phase 1 | 5 | Istari Oncology, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03671720 | Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden | withdrawn | Early Phase 1 | 0 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | not yet recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06224738 | Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases | unknown | Early Phase 1 | 9 | First People's Hospital of HangzhouOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02384473 | Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma | completed | Early Phase 1 | 25 | University of Southern CaliforniaOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03870529 | High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Early Phase 1 | 8 | University of UtahOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06194630 | Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04803123 | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL | terminated | Early Phase 1 | 3 | Dorothy Sipkins, MD, PhDOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06171282 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03928210 | Digoxin Induced Dissolution of CTC Clusters | completed | Early Phase 1 | 58 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04663126 | Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma(Tilmanocept) | terminated | Early Phase 1 | 5 | John O. PriorOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05773703 | Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer | completed | Early Phase 1 | 23 | Ratio Therapeutics, Inc.INDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib(Mel61) | terminated | Early Phase 1 | 8 | Craig L Slingluff, JrOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02469129 | PET Imaging of PARP Activity in Cancer | unknown | Early Phase 1 | 50 | Washington University School of MedicineOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04341129 | Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine) | completed | Early Phase 1 | 50 | University of ChicagoOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04267874 | Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study | completed | Early Phase 1 | 96 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03724409 | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases | terminated | Early Phase 1 | 3 | Sandeep LaroiaOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04977882 | Abdominal Drainage, Postoperative Antibiotico-prophylaxis and CME With D3 Lyphadenectomy Effect on Gastrointestinal Function in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis for Right Colon Cancer | completed | Early Phase 1 | 36 | University of Rome Tor VergataOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03395847 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | completed | Early Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06117878 | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma | unknown | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114173 | Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma | unknown | Early Phase 1 | 15 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05643248 | To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects | completed | Early Phase 1 | 9 | Nanexa ABINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06104241 | BGT007 Cells for the Treatment of Refractory Digestive System Tumors | recruiting | Early Phase 1 | 14 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06098898 | Safety and Efficacy of NK510 to Treat Gastric Cancer | unknown | Early Phase 1 | 9 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04074564 | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | unknown | Early Phase 1 | 60 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04006769 | Entacapone Combination With Imatinib for Treatment of GIST | completed | Early Phase 1 | 5 | Xiangya Hospital of Central South UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Stony Brook UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06054984 | TCR-T Cells in the Treatment of Advanced Pancreatic Cancer(GB3010-02) | unknown | Early Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06062602 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | completed | Early Phase 1 | 15 | Presage BiosciencesINDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 21, 2024source: clinicaltrials